^SINGAPORE, March 08, 2023 (GLOBE NEWSWIRE) — Novotech, the leading, im
Asia Pacific-based biotech contract research organization (CRO),
will be at BIO Europe (March 20-22, 2023) with biotech companies in the
clinical stage coincide and the benefits of recent
Presenting Novotech’s expansion in Europe.
At JPMorgan earlier this year, Novotech announced the acquisition of EastHORN, a
European CRO with clinical, medical and regulatory expertise
several strategically important locations on the continent.
EastHORN, which retains its brand, is now a Novotech company and will
integrated into Novotech’s systems and processes so that customers benefit from the
Working with just one CRO worldwide.
The acquisition is part of Novotech’s global expansion program. EastHORN
was founded in 2004 and has over 250 employees.
The acquisition of EastHORN means customers in the biotechnology industry
throughout Europe and the USA access to the unique and unparalleled offer
Have early to late stage CRO services from Novotech. The
However, the focus is on the Asia-Pacific region, where the
Company has a good reputation for expedited implementation
high-quality clinical studies.
dr John Moller, CEO of Novotech said:
?This acquisition is a strategic step to further our CRO activities
to expand and our customers from the biotechnology industry within the countries
of Asia-Pacific, North America and Europe in relation to their
to support global drug development programs with expertise.
We have worked together for many years and share a clinical culture
Excellence in biotechnological drug development.
Customers can now rely on our exceptional European infrastructure,
our local knowledge, our relationships with trial sites and our access to
different patient groups.”
Novotech has decades of experience in biotechnology
drug development, has established relationships with trial sites and
investigators, access to large patient populations and follow-up
Project management approach that focuses on problem solving, ownership and
flexibility focused. Consistent investments in progressive
Training and technology provide exceptional full-service CRO
Solution in the field of biotechnology.
Novotech has recently been recognized with major CRO awards including
Frost & Sullivan’s “Asia-Pacific Biotech CRO of the Year” award,
ranking as one of the top 10 CROs among the world’s leading CROs,
the nomination as a finalist at the prestigious Scrip Awards and the
Presentation of the Gene & Cell Therapy Excellence Award.
In Asia Pacific, Novotech has more than 50 Leading Site Partnership
Agreements with major medical research institutions
closed, which offer the sponsors exclusive advantages.
About Novotech Novotech-CRO.com (https://novotech-cro.com/)
Novotech is the leading CRO in Asia Pacific with worldwide
Implementation options. Novotech is a clinical contract research organization
with laboratories, Phase I facilities, consulting services for the
Drug development and FDA approvals expertise and has experience
with over 5,000 clinical projects, including clinical trials of the
Phases I to IV and bioequivalence studies. Novotech is able to customers from
the biotechnology industry in conducting clinical trials in Asia
Pacific Rim, USA and Europe. Novotech has
more than 3,000 employees worldwide and 33 offices in the USA, Europe and the
Asia Pacific.
Visit https://novotech-cro.com/contact for more information
°